We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia.
- Authors
AKTIMUR, Sude Hatun; BAYCELEBI, Deniz; GUNES, Ahmet Kursad; YILDIZ, Levent; TURGUT, Mehmet
- Abstract
According to newly defined features of bone marrow (BM) histology, some of the patients who were previously diagnosed with essential thrombocythemia (ET) were accepted as early/prefibrotic PMF in recent publications. The aim of this study was to explore actual rate of pre-PMF according to the 2016 revised WHO criteria. Demographic characteristics of 160 patients diagnosed with ET between 2000-2017; laboratory values; cytogenetic profile; the treatments using; disease-related thromboembolic complications; progression of the disease to MF and AML; mortality rates and cause were recorded retrospectively. The diagnosis of pre-PMF or ET was confirmed by BM morphology and clinical follow-up. BM biopsy samples obtained during the initial diagnosis were available in 107 cases. 53 cases with inaccessible BM biopsies were excluded from the study. The distribution of female/male in cases of ET was 46/28. The incidence of progression to AML was higher in pre-PMF patients. (Progression to AML: PMF 15.15%; ET 4.05%; p= 0.044). The mean duration of progression-free survival in patients with progression to AML or PMF in pre-PMF patients was 52.1±7.37 months; ET was 62.44±10.20 months. Approximately 30% of patients previously diagnosed with ET consisted of pre-PMF patients. Anemia, high LDH level, and splenomegaly are parameters that can be used in the differential diagnosis of PMF.
- Subjects
THROMBOCYTOSIS; OVERALL survival; MYELOFIBROSIS; DIAGNOSIS; BONE marrow; MYCOSIS fungoides
- Publication
UHOD: International Journal of Hematology & Oncology / Uluslararasi Hematoloji Onkoloji Dergisi, 2021, Vol 31, Issue 3, p139
- ISSN
1306-133X
- Publication type
Article
- DOI
10.4999/uhod.215031